Search Results 1621-1630 of 14651 for anti-TNF drugs

1. Clinical Trials - Mayo Clinic Research

   Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory Loss (A4). The A4 study is investigating the effect of anti-amyloid treatment ...

2. Emtricitabine And Tenofovir Alafenamide (Oral Route) Description and Brand Names - Mayo Clinic

   Emtricitabine and tenofovir alafenamide combination is used together with other medicines to treat human immunodeficiency virus (HIV) infection. HIV is the ...

3. Pacritinib (Oral Route) Side Effects - Mayo Clinic

   Side Effects. Drug information provided by: Merative, Micromedex®. Along with its needed effects, a medicine may cause some unwanted effects. Although not ...

4. Safety Study of Chimeric Natriuretic Peptide(CD-NP) in Stable LVAD Patients - Mayo Clinic

   ... anti-fibrotic and anti-remodeling drug as co-therapy during LVAD support. Participation eligibility. Participant eligibility includes age, gender, type and ...

5. A Study of Nirogacestat for Adults With Desmoid Tumor/Aggressive Fibromatosis (DT/AF) - Mayo Clinic

   ... therapy must be resolved to ≤ Grade 1 or clinical baseline. Participants who are receiving chronic nonsteroidal anti-inflammatory drugs (NSAIDs) as treatment ...

6. A Study of the Safety and Effectiveness of Iontophoretic Dexamethasone Phosphate Ophthalmic Solution for Non-Infectious Anterior Uveitis - Mayo Clinic

   Drugs & Supplements A-Z · Health Books · Healthy Living Program · Mayo Clinic Health ... anti-hypertensive medications in the study eye; Is a known steroid ...

7. Estradiol And Norethindrone (Transdermal Route) Description and Brand Names - Mayo Clinic

   Description and Brand Names. Drug information provided by: Merative, Micromedex®. US Brand Name. Combipatch. Canadian Brand Name. Estalis ...

8. A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors - Mayo Clinic

   Drugs & Supplements A-Z · Health Books · Healthy Living Program · Mayo Clinic ... anti-cancer therapy for 2 years 14. Pregnant or lactating. If ?-HCG is ...

9. A Study to Evaluate the Impact of a Pharmacist-led Oral Anticancer Medication (OAM) Program on Patient Outcomes - Mayo Clinic

   ... therapy. Exclusion Criteria: Any patient who had previously received oral anti-cancer (OAM) therapy. Patient age < 18 years. Pregnancy. Participating Mayo ...

10. Lenalidomide Plus Rituximab Followed by Lenalidomide Versus Rituximab Maintenance for Relapsed/Refractory Follicular, Marginal Zone or Mantle Cell Lymphoma. - Mayo Clinic

    Systemic anti-lymphoma therapy within 28 days or use of antibody agents within 8 weeks use of radioimmunotherapy within 3 months; Known seropositive for or ...